Amarin Stock Earnings Reports

Amarin reported Q1 2026 progress driven by its new two-pronged operating model: a cash-generating U.S. commercial franchise and a fully partnered international commercialization strategy anchored by an exclusive Recordati agreement in Europe. The company has substantially completed its global restructuring and remains on track to realize ~$70 million of annual operating expense savings by June 30, 2026. Financial highlights: cash and investments of $308 million, no debt, positive operating cash flow for the second consecutive quarter ($6.4 million in Q1), and management expects positive cash flow for full-year 2026. U.S. performance: VASCEPA remains the market leader in icosapent ethyl with a 48% market share (up from 42% year-over-year) and branded prescriptions up 17% vs. Q1 2025 despite generic competition; the company is maintaining key payer exclusives through 2026 and is not pursuing an authorized generic at this time. International performance: Recordati has launched VAZKEPA in 10 European countries with Q1 European revenue up 113% sequentially (Q1 2026 vs Q4 2025) and initial supply shipments are driving early momentum; additional launches and regulatory filings are in progress across Asia-Pacific and other regions. Clinical and market environment: newly updated 2026 ACC/AHA lipid management guidelines explicitly position icosapent ethyl as the only triglyceride-lowering agent proven to reduce cardiovascular event risk on top of statin therapy, which management believes supports continued uptake over time. Management is engaged with Barclays on strategic alternatives to enhance shareholder value and is open to potential capital-return options once appropriate opportunities arise.